W Kassouf
Overview
Explore the profile of W Kassouf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
181
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marcq G, Kassouf W, Roumiguie M, Pradere B, Mertens L, Albisinni S, et al.
Actas Urol Esp (Engl Ed)
. 2025 Feb;
49(2):501701.
PMID: 39938643
Introduction: Until recently there was no recommended adjuvant therapy for patients with lymph nodes metastasis (ypN+) following neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). The...
2.
Mir M, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey A, Mertens L, et al.
Eur Urol Focus
. 2022 Feb;
8(5):1559.
PMID: 35181282
No abstract available.
3.
Mir M, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey A, Mertens L, et al.
Eur Urol Focus
. 2020 Aug;
7(6):1347-1354.
PMID: 32771446
Background: Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) is associated with improved overall and cancer-specific survival. The post-NAC pathological stage has previously been reported to be a major...
4.
Lotan Y, Inman B, Davis L, Kassouf W, Messing E, Daneshmand S, et al.
J Urol
. 2019 Oct;
203(3):625-626.
PMID: 31651229
No abstract available.
5.
Vasdev N, Zargar H, Noel J, Veeratterapillay R, Fairey A, Mertens L, et al.
World J Urol
. 2018 Jun;
37(1):165-172.
PMID: 29882105
Background: Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer improves all-cause and cancer specific survival. We aimed to evaluate whether the detection of carcinoma in situ (CIS) at the...
6.
Dragomir A, Rocha J, Vanhuyse M, Cury F, Kassouf W, Hu J, et al.
Curr Oncol
. 2017 Sep;
24(4):240-248.
PMID: 28874892
Introduction: Since just after the year 2000 in Quebec, the management of metastatic castration-resistant prostate cancer (mcrpc) has evolved considerably, with the inclusion of docetaxel-based chemotherapy, bone-targeted therapies (zoledronic acid...
7.
Santos F, Dragomir A, Kassouf W, Franco E, Aprikian A
Curr Oncol
. 2015 Feb;
22(1):e20-6.
PMID: 25684993
Background: Evidence shows that wait times before bladder cancer surgery have been increasing, and wait time can negatively affect survival. We aimed to determine if a long delay caused by...
8.
Xylinas E, Cha E, Sun M, Rink M, Trinh Q, Novara G, et al.
Br J Cancer
. 2012 Nov;
107(11):1826-32.
PMID: 23169335
Background: In pT1-T3N0 urothelial carcinoma of the bladder (UCB) patients, multi-modal therapy is inconsistently recommended. The aim of the study was to develop a prognostic tool to help decision-making regarding...
9.
Jewett M, Finelli A, Kollmannsberger C, Wood L, Legere L, Basiuk J, et al.
Can Urol Assoc J
. 2012 Mar;
6(1):16-22.
PMID: 22396361
No abstract available.
10.
Yafi F, North S, Kassouf W
Curr Oncol
. 2011 Feb;
18(1):e25-34.
PMID: 21331269
Urothelial cancer of the bladder is the 4th most common malignancy in American men and the 9th most common in women. Although it is a chemosensitive disease, advanced bladder cancer...